TMCnet News
ILÚM Health Solutions Acquires TeqqaILÚM Health Solutions, a provider of innovative technology and services to support infectious disease management, today announced it has acquired Teqqa LLC, which provides precision analytics for infectious disease management. Teqqa has been a development partner with ILÚM since the latter's founding; this acquisition formalizes and strengthens the ongoing relationship. Details of the transaction were not disclosed. "This acquisition helps reinforce ILÚM's vision to transform the way hospitals manage infectious diseases," says Paul Edwards, managing director, ILÚM. "The acquisition strengthens ILÚM's ability to help hospitals efficiently target patients and accelerate time to appropriate interventions; efficiently and consistently track performance, prescribing, and patient outcomes; and enhance timely communication and clinical collaboration within the workflow." ILÚM, created by Merck's Healthcare Services and Solutions (HSS) division, is collaborating with healthcare providers to improve infectious disease outcomes through the use of clinical decision support and electronic patient data, as well as tech-enabled solutions to facilitate antimicrobial stewardship programs and sepsis management. The Centers for Disease Control and Prevention estimates that annually in the United States we face 2 million illnesses, 23,000 deaths and $35 billion in lost productivity - all attributable to antibiotic resistance. Teqqa has deep experience working with hospitals to implement disease surveillance solutions and turn lab and medication data into actionable information. One example is Teqqa's Precision Antibiotic Therapy (PAT™) analytic, which integrates patient-specific risk factors from the longitudinal record to offer timely insights for antibiotic use. "In antibiotic stewardship, our ultimate goal is to make sure the right patients get the right antibiotic at the right time," says Dr. Keith Hamilton, associate healthcare epidemiologist and director of Antimicrobial Stewardship at the Hospital of the University of Pennsylvania, which has been collaborating with Teqqa since 2014. "These solutions make previously unavailable data useable at the point of prescription. Our clinicians now have data at their fingertips to help them make the most appropriate decisions when it matters most. We look forward to collaborating with ILÚM to further validate how these solutions support the best possible outcomes for our patients."
About ILÚM Health Solutions
About Teqqa
About Merck
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2016 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC (News - Alert)) available at the SEC's Internet site (www.sec.gov).
View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005488/en/ |